Us Congress 2023-2024 Regular Session

Us Congress House Bill HB5647

Introduced
9/21/23  
Refer
9/21/23  

Caption

Childhood Cancer Clinical Trials Act

Impact

The proposed amendments would have significant implications for both private health insurance plans and Medicare. Specifically, the legislation requires that group health plans provide coverage under the same cost-sharing terms as if the services were rendered by in-network providers. This change is intended to ease the financial burden on families who have children diagnosed with rare pediatric diseases, enabling them to seek essential medical care without financial penalties against them for opting for out-of-network treatment when necessary. This could potentially lead to better outcomes for pediatric patients as they access innovative therapies through clinical trials.

Summary

House Bill 5647, named the 'Childhood Cancer Clinical Trials Act', seeks to amend Title XXVII of the Public Health Service Act to mandate out-of-network coverage for routine patient costs incurred by individuals diagnosed with rare pediatric diseases who are participating in approved clinical trials. The bill's introduction reflects a growing recognition of the challenges faced by children with rare diseases, who often have limited treatment options. By ensuring that these individuals can participate in clinical trials without incurring exorbitant out-of-pocket expenses, the bill aims to enhance patient access to potentially life-saving treatments and research opportunities.

Contention

While the bill has been generally well-received in its intent to support families with children suffering from rare diseases, there may be some contention regarding its implementation. Critics may argue that requiring coverage for out-of-network costs could drive up insurance premiums or create disparities in access, particularly in areas where specialized care is scarce. Additionally, stakeholders may express concerns regarding the definitions of 'rare pediatric diseases' and 'approved clinical trials,' emphasizing the need for clarity to avoid confusion among health providers and insurance companies.

Notable_points

Furthermore, the effective date for these amendments is set for January 1, 2024, meaning that health insurance providers will have a limited window to adjust their policies and procedures accordingly. The introduction of a voluntary network of participating providers is also part of the bill, suggesting a possible collaborative approach to ensure that patients can access services from a variety of providers while still complying with the new insurance requirements.

Companion Bills

No companion bills found.

Previously Filed As

US SB583

Clinical trials.

US SB645

Coverage of routine care related to certain clinical trials by health insurance policies and plans. (FE)

US HB2438

MEDICAID-CLINICAL TRIALS

US SB00260

An Act Concerning Health Insurance Coverage For Routine Patient Care Costs For Certain Clinical Trial Patients.

US SB00021

An Act Concerning Health Insurance Coverage For Routine Patient Care Costs For Certain Clinical Trial Patients.

US HB3521

Clinical Trial Modernization Act

US HB8412

Clinical Trial Modernization Act

US HB4714

Pediatricians Accelerate Childhood Therapies Act of 2023

US H649

Ensure Timely/Clinically Sound Utiliz. Review

US HB3503

NIH Clinical Trial Diversity Act of 2023

Similar Bills

AZ SB1148

CORP; defined contributions

CA AB340

Golden State Scholarshare Trust: Personal Income Tax Law: gross income: deductions.

CA AB2835

Motels and hotels: publicly funded shelter programs.

CA AB910

CalWORKs: welfare-to-work activities: hours.

CA SB1463

Developmental services: Self-Determination Program: Deputy Director of Self-Determination.

CA SB371

Transportation network companies: insurance coverage.

AZ HB2015

Retirement plans; plan election; rehire

CA AB1773

CalWORKs: supportive services.